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ABSTRACT:  
Chronic Kidney Disease (CKD) is associated with abnormalities in bone quantity and quality 
leading to increased fractures.  Recent studies suggest abnormalities of Wnt signaling in animal 
models of CKD and elevated sclerostin levels in patients with CKD.  The goal of this study was 
to evaluate the effectiveness of anti-sclerostin antibody treatment in an animal model of 
progressive CKD with low and high parathyroid hormone (PTH) levels.  Cy/+ male rats (CKD) 
were treated without or with calcium in the drinking water at 25 weeks of age to stratify the 
animals into high PTH and low PTH groups, respectively, by 30 weeks.  Animals were then 
treated with anti-sclerostin antibody at 100 mg/kg IV weekly for 5 doses, a single 20 ug/kg 
subcutaneous dose of zoledronic acid, or no treatment and sacrificed at 35 weeks.  As a positive 
control, the efficacy of anti-sclerostin antibody treatment was also evaluated in normal 
littermates.   The results demonstrated that the CKD animals with high PTH had lower calcium, 
higher phosphorus, and lower FGF23 compared to the CKD animals with low PTH.  Treatment 
with anti-sclerostin Ab had no effect on any of the biochemistries, while zoledronic acid lowered 
dkk-1 levels.  The anti-sclerostin antibody increased trabecular BV/TV, trabecular bone 
formation rate, and cortical geometry in animals with low, but not high, PTH.  Neither anti-
sclerostin antibody nor zoledronic acid improved biomechanical properties in the animals.  
Cortical porosity was severe in high PTH animals and unaffected by either treatment.  In 
contrast, in normal animals treated with anti-sclerostin antibody, there was an improvement in 
bone volume, cortical geometry, and biomechanical properties. In summary, this is the first study 
to test the efficacy of anti-sclerostin Ab treatment on animals with advanced CKD.  We found 
efficacy in improving bone properties only when the PTH levels were low.   
 
Key Words:  Renal Osteodystrophy, parathyroid hormone, sclerostin, Wnt, FGF23, CKD-MBD    
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INTRODUCTION: 
 Chronic Kidney Disease affects over 20 million Americans and many of these individuals 
are older and at risk for fragility fractures(1).  CKD-Mineral Bone Disorder is a systemic disease 
in patients with estimated glomerular filtration rates (eGFR) < 60 ml/min (CKD stage 3-5) that 
manifests as abnormal biochemistries, renal osteodystrophy, and extraskeletal calcification(2,3).  
The potential contribution of renal osteodystrophy, versus osteoporosis, in the pathogenesis of 
fragility fractures in patients with impaired kidney function has led to confusion on the treatment 
of bone loss.   In human trials, secondary analyses of individuals with CKD stage 3-5 have found 
a beneficial effect of bisphosphonates, raloxifene, and denosumab  in post-menopausal women 
with reduced fractures and improved bone mineral density without adverse consequences(4-8).  
However, these individuals were enrolled into the studies based on normal kidney function and 
parathyroid hormone levels and only subsequently identified to have CKD in post hoc analyses.  
With normal PTH levels, one can argue that the change in GFR is related to age based decline in 
kidney function rather than intrinsic disease and therefore not representative of CKD-MBD.  
 The role of PTH in renal osteodystrophy has been the focus of therapies for many years.  
Low and high levels of PTH have been correlated with low and high bone formation rates, and 
lowering elevated PTH with calcitriol and its analogs or cinacalcet is currently the primary 
therapy for renal osteodystrophy.  Clinical practice guidelines recommend correction of elevated 
PTH prior to any consideration for other bone/anti-osteoporotic treatment in patients with bone 
loss(1).  The concern over the use of anti-resorptives has stemmed from reports that these agents 
may ‘over suppress’ PTH and cause adynamic bone disease(1), which may be associated with 
bone fractures and extra-skeletal calcification.  Unfortunately, PTH, despite being a major 
contributor to the pathogenesis of renal osteodystrophy, lacks ideal discriminatory ability for the 
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differentiation of low and high turnover and thus misclassification is common(9).  Therefore, 
treatments that are efficacious in improving or ameliorating bone loss regardless of the PTH are 
needed.   
 In addition to elevated PTH, patients with CKD also have elevated FGF23 and sclerostin 
levels.  PTH stimulates FGF23 secretion from osteocytes via a sclerostin mediated 
pathway(10,11) and suppresses sclerostin secretion from osteocytes(12).    Sclerostin levels are 
increased in CKD compared to normal individuals with osteoporosis, and levels are inversely 
associated with PTH levels(13).  Sclerostin, the protein product of the gene SOST, binds to 
LRP5/6 on the osteocyte to competitively inhibit the binding of Wnt ligands.  Normally, Wnt 
binding to LRP5/6 leads to stabilization of β-catenin (canonical pathway), and regulation of 
normal bone accrual via osteoblast differentiation.  In the presence of sclerostin, the β-catenin is 
degraded and mesenchymal stem cell differentiation to mature bone cells is inhibited (Reviewed 
in(14)).   In animal models, sclerostin deletion enhances bone accrual(15-19) and in early human 
trials(20)  treatment with an antibody to sclerostin is anabolic.  Given that sclerostin levels are 
elevated in blood of patients with CKD(21) and bone of patients and animals with CKD(22) the 
anabolic agent anti-sclerostin antibody may be efficacious in all forms of renal osteodystrophy 
independent of PTH and bone turnover.  To test this hypothesis we used a slowly progressive 
model of CKD-MBD, manipulating the PTH to low and high levels.  We then compared 
treatment with anti-sclerostin Ab, zoledronic acid, or no treatment on biochemical, vascular 
calcification, and bone outcomes.   
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MATERIALS AND METHODS: 
Animal model and experimental design: 
  We tested the hypothesis that anti-sclerostin antibody is efficacious in preventing bone 
loss in animals with both high PTH and low PTH, the latter induced by calcium in the drinking 
water.  We have previously shown that these two extremes of PTH lead to high and low 
activation frequencies and bone formation rates, respectively(23,24).  Briefly, male Cy/+ rats, 
Han:SPRD rats with autosomal dominant polycystic kidney disease, and normal age matched 
Han:SPRD rats (NL) were used for this study. Male heterozygous rats (Cy/+) develop 
characteristics of CKD (azotemia) around 10 weeks of age which progresses gradually.  By 35 
weeks, as we have previously reported(25-27), untreated CKD animals at 35 weeks of age have 
biochemical abnormalities that parallel advanced CKD in humans:  in the CKD animals versus 
NL littermates, the BUN was 49.3 ± 8.3 vs 22.0 + 4.7 mg/dl, the PTH was 1560 ± 859 vs 132 ± 
67 pg/ml; the phosphorus was 8.4 ± 1.8 vs. 3.6 + 0.6 mg/dl; and the calcium was 8.99 ± 2.0 vs. 
10.3 ± 0.5 mg/dl.     
For the current study, animals were placed on a standard casein diet (Purina AIN-76A; 
0.53% Ca and 0.56% P) at 24 weeks of age which has been shown to produce a more consistent 
disease in this model(25).  At 25 weeks of age, with an estimated kidney function of 35% of 
normal, animals were randomly assigned to 3% calcium in the drinking water or normal water to 
suppress or maintain the hyperparathyroid state (Figure 1).  The additional calcium intake based 
on average water consumption is 1.98 ± 0.57 g/day.  At 30 weeks of age with estimated kidney 
function at 20% of normal, animals in both the low and high PTH groups were randomly 
assigned to anti- sclerostin Ab (Scl-Ab; 100 mg/kg given by tail vein IV q week for 5 total doses; 
Novartis Institutes for BioMedical Research, Novartis Pharma AG), zoledronic acid (ZOL; 20 
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µg/kg body weight given subcutaneously once at week 30, a dose previously shown to suppress 
bone remodeling in this model (23)), or no treatment (CTL) for 5 weeks. In addition, we studied 
age-matched normal (NL) littermate animals as a positive control for the anti-sclerostin Ab.  
Each group had a final n of 9 to 12 animals (Fig 1);  1 animal died suddenly in each of three 
groups:  the CKD group treated with zoledronic acid, the CKD group treated with calcium and 
anti-sclerostin Ab, and the CKD group treated without calcium and anti-sclerostin Ab.  This is 
consistent with our previous studies.  In addition, two animals had to be sacrificed early in the 
anti-sclerostin treatment groups due to saphenous vein inflammation resulting from 
pharmacokinetic blood sampling.  These animals were not included in the final analyses.  At 35 
weeks of age all animals were euthanized by an overdose of sodium pentobarbital.   All 
procedures were reviewed and approved by the Indiana University School of Medicine 
Institutional Animal Care and Use Committee.   
Tissues collection and analysis:   
At sacrifice at 35 weeks, blood was collected by cardiac puncture.  Left tibiae were 
placed in 10% neutral buffered formalin for 48 hours and then changed to 70% ethanol for 
imaging followed by histological processing. Right femora were wrapped in saline-soaked gauze 
and frozen for later biomechanical analyses and CT evaluation. Left ventricular mass index 
(LVMI) was determined by dividing total heart weight by body weight. To quantify aorta and 
heart calcification, proximal segments of the ascending aorta were snap frozen and the degree of 
calcification determined biochemically as previously described (27,28).  
Serum and urine biochemical measurements:   
Pharmacokinetics analyses of the Scl-Ab were performed by measuring levels of the anti-
sclerostin Ab in serum of eight CKD rats after the first and last dose at 6 and 24 hours post 
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injection using a custom made immunoassay (Novartis Pharma AG). Blood plasma was analyzed 
for BUN, calcium, phosphorus, and creatinine using colorimetric assays (Point Scientific, 
Canton, MI, USA, or Sigma kits). Intact PTH was determined by ELISA (Alpco, Salem, NH, 
USA). FGF23 was assessed with a two-site assay (Immunotopics, San Clemente, CA, USA). 
Dickkopf-related protein family-1 (Dkk-1) and Sclerostin levels were measured by ELISA (Enzo 
Life Sciences, Farmingdale NY; R&D systems, Minneapolis, MN, respectively).   
Computed tomography (CT):   
Morphological parameters of the proximal tibia and femoral mid-diaphysis were assessed 
using high-resolution microCT (Skyscan 1172) as previously described (27). Scans were 
obtained using a 60kV x-ray source (167 µA), an angular range of 180 degrees (rotational steps 
of 0.70 degrees with 2 frame averaging) with a 12-µm pixel size and 0.5mm Al filter. Projection 
images were reconstructed using standard Skyscan software (NRecon). A 1mm region of interest 
of the proximal tibia (located ~ 0.5 mm distal to the growth plate) was analyzed by manually 
segmenting the trabecular bone from the cortical shell and calculating trabecular bone volume 
normalized to total volume (BV/TV) in accordance with recommended guidelines(29). The most 
distal slice of the region of interest was analyzed for cortical porosity.    Scans of the femoral 
diaphysis were conducted with similar scan settings to assess geometry (bone area, perimeter, 
cross-sectional moment of inertia) for normalization of mechanical properties.   Measures were 
made in accordance with recommended guidelines(30).    
Biomechanics:   
Femoral diaphysis mechanical properties were assessed in 4-point bending studies on a 
servo-hydraulic test system (Test Resources).  Bones were thawed, hydrated in saline, and then 
placed posterior surface down on bottom supports (span = 18 mm).  The upper supports (span = 
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6 mm) were brought down in contact with the specimen’s anterior surface, and then testing was 
conducted at a displacement rate of 2 mm/min.  Force versus displacement data was collected at 
10 Hz and structural parameters were determined from curves using a customized MATLAB 
program. Material properties were estimated using standard equations(31).   
Bone Histomorphometry:  
Proximal tibiae were embedded in methylmethacrylate for sectioning as previously 
described(23,32). The proximal tibial metaphysis was thin sectioned (4 µm) and mounted 
unstained using non-fluorescent medium. Sections were analyzed using a microscope interfaced 
with a semiautomatic analysis system (Bioquant OSTEO 7.20.10, Bioquant Image Analysis Co.).  
For trabecular bone analyses, a region of interest of ~ 8 mm2 within the secondary spongiosa (~ 
0.5 mm distal to the growth plate) was outlined, and then measures of single- and double-label 
perimeter (sL.Pm, dL.Pm), total bone perimeter (B.Pm) and interlabel width (Ir.L.Wi) were 
conducted. From these primary measurements, derived parameters were calculated as: 
mineralizing surface (MS/BS = [1/2sL.Pm + dL.Pm]/B.Pm; %), mineral apposition rate (MAR 
=Ir.l.W/days between labels; µm/day), and bone formation rate (BFR/BS = MAR x MS/BS x 
3.65; µm3/µm2/yr). All parameters were measured and calculated in accordance with ASBMR 
recommended  standards (33).  
 Real time (quantitative) RT-PCR analysis of SOST expression: 
Total RNA was isolated from tibiae using miRNeasy Mini kit (Qiagen, Valencia, CA). 
after flushing out the bone marrow.  The SOST expression in bone was determined by real time 
PCR using 1 ug of total RNA in TaqMan Reverse Transcription reagent (Applied Biosystems, 
Foster City, CA).  Target-specific PCR primer for SOST was obtained from Applied Biosystems.  
Real-time PCR amplification was performed using TaqMan Gene Expression Assays (TaqMan 
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MGP probes, FAM dye-labeled) using Applied Biosystems ViiA-7 RealTime PCR system 
(Applied Biosystems).  The cycle number at which the amplification plot crosses the threshold 
was calculated (CT), and the ∆∆CT method was used to analyze the relative changes in gene 
expression using β-actin as a housekeeping gene. 
Western blot analysis of β-catenin activation in bone tissue: 
To determine the effect of sclerostin antibody treated animals on β-catenin signaling in 
bone tissue, proteins were isolated from tibiae by homogenizing the tissue with RIPA buffer  
using the Bullet Blender (Next Advance, Inc, Averill Park, NY) according to manufacturer’s 
instructions.  The β-catenin activation was determined by Western blot as we previously 
described (34) using phosphorylated β-catenin antibody.  Briefly, the blots were incubated with 
antibody against pSer33/37 β-catenin  (1:1000, Cell Signaling Technology, Danvers, MA) 
overnight at 4oC followed by incubating with peroxidase conjugated secondary antibody (1:5000 
dilution), and immunodetection with the Enhanced Chemiluminescence Prime Western blot 
Detection Reagent (Amersham, Piscataway, NJ).  The band intensity was analyzed by ChemiDoc 
MP Imaging System (Imaging Lab 4.0, Bio-Rad, Richmond, CA).  	  
	  
Statistics:   
All analyses were run using SigmaStat software.  The two CKD groups (high and low 
PTH) at week 30, prior to drug treatment and the normal animals with and without Scl-Ab were 
compared by t-test.  The six CKD groups at 35 weeks were analyzed by two-way ANOVA after 
log transformation for non normally distributed data.  The two groups compared were  PTH 
status (low vs. high), and  treatment effect (Scl-Ab, Zol, CTL) in order to test the efficacy of 
treatments in the setting of low and high PTH.  Fisher’s Post hoc tests were  done for within 
group comparisons.  Correlations were done by Pearson Product after log transformation if 
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appropriate.  A priori α-levels were set at 0.05.  Data are presented as means and standard 
deviation. 
 
RESULTS: 
Biochemical outcomes:  
As detailed in Figure 1, at 25 weeks of age, the CKD animals had established secondary 
hyperparathyroidism.  After 5 weeks on oral calcium, the PTH was suppressed to 120 ± 100 
pg/ml in the calcium treated group compared to 759 ± 778 in the high PTH (p < 0.05).  At 35 
weeks, the calcium treated animals (low PTH groups) had a further decline in PTH compared to 
week 30, whereas the non-calcium (high PTH groups) animals had a further rise in PTH (overall 
p < 0.001; Figure 1).  There was no difference of drug treatment on PTH with the exception of a 
slightly more elevated PTH in the high PTH group treated with anti-sclerostin Ab compared to 
control (p = 0.03).  At 35 weeks, there was no difference in the level of BUN among CKD 
groups, indicating no adverse effect on kidney function (data not shown).  Figure 2 shows the 
high PTH (left set of bars) compared to low PTH groups (right set of bars) at 35 weeks for 
calcium (Figure 2A), phosphorus (2B), FGF23 (2C), and Dkk-1 (2D).  The high vs. low PTH 
groups were different for calcium (p = 0.016), phosphorus (p = 0.034), and FGF23 (p< 0.001), 
but the drug effect was not significant for any of these and there was no interaction between PTH 
group and drug treatment by 2 way ANOVA.   
As expected, serum levels of Dkk-1 and sclerostin were both elevated in CKD compared 
to NL animals (p = 0.04, p < 0.001).  In the CKD animals, Dkk-1 levels were unaffected by PTH 
group (p = 0.52), but were affected by drug treatment (overall p = 0.004; ZOL different than Scl-
Ab and CTL, both p < 0.03; Figure 2D).    There was a weak correlation between Dkk-1 and 
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FGF23 (r = 0.32, p = 0.01) and calcium (r = 0.25, p = 0.047), a modest correlation with kidney 
function (BUN; r = 0.51, p < 0.001), but no significant correlation with PTH.  The sclerostin 
levels were inconsistent in the groups treated with the anti-sclerostin Ab due to probable cross-
reactivity with the antigen-antibody complex and the assay in both the CKD and the NL animals 
and thus only the other groups were evaluated.   The sclerostin levels in the high PTH group 
were 458 ± 122, high PTH with zol= 563 ± 339, low PTH 249 ± 122, and low PTH with zol = 
260 ± 102 (p = 0.005).  There was a strong positive correlation of the log sclerostin vs log PTH (r 
= 0.73, p < 0.001; Figure 3A). Given the assay limitations, we measured SOST gene expression 
in the bone by real time PCR to determine if anti-sclerostin Ab had any effect on SOST gene 
expression.  The results showed an increase in SOST expression with the administration of the 
anti-sclerostin Ab, but only in the calcium treated low PTH animals (Figure 3B).    
 Cardiovascular outcomes:  As previously reported, the left ventricular mass index was 
greater in untreated CKD animals (3.59 ± 0.12) compared to NL animals (2.99 ± 0.24) (p < 
0.001).  Within the CKD groups there was no difference by PTH or by drug treatment by two 
way ANOVA (p = 0.26).    Similarly, there was a difference between the aorta arch calcification 
between untreated CKD and NL animals (p = 0.01) but within the CKD animals no effect on 
calcification by PTH (p = 0.15) or treatments (p = 0.26) by 2 way ANOVA (Figure 4).  There 
was a trend towards reduction in calcification by both zoledronic acid and anti-sclerostin Ab in 
the low PTH group.   Eighty percent of animals in the low PTH control group had significant 
calcification (defined as > 5.26 umol/g which is the normal littermate average value of mean + 
2SD), compared to 20-30% of animals in the other groups (boxes in bars in Figure 4).   
Bone outcomes: As we have previously reported (27), the trabecular BV/TV of the 
untreated CKD animals was not different from the normal animals (9.1 ± 4.1 vs. 10.2 ± 4.2%, 
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respectively) but the cortical porosity was greater (CKD: 2.37 ± 1.74 vs NL: 0.97 ± 0.39, p = 
0.02).  In the CKD animals at 35 weeks, there was an effect of both PTH (p < 0.0001) and drug 
treatment (p = 0.03) on trabecular BV/TV (Figure 5A).  The within group difference was 
significant for only Anti-sclerostin Ab vs. CTL (p = 0.008).  The same pattern existed for 
femoral mid-diaphysis cortical bone area and cross-sectional moment of inertia (Table 1).  In 
contrast, proximal tibia cortical porosity as well as all mechanical and geometrical parameters of 
the femoral mid-diaphysis showed significant PTH effects (p < 0.001 for all) but only a trend 
towards an effect of drug treatment (p = 0.9) (Figure 5B, 5C, Table 1). The periosteal perimeter 
was not different, but the endocortical perimeter was greater in the high PTH group compared to 
the low PTH group (p < 0.001) with no effect of treatment due to the wide variability (Figure 
5D).  Corresponding cross sectional microCT images are shown in Figure 5E. As a positive 
control, NL animals given similar doses of Scl-Ab, demonstrated a robust increase in trabecular 
BV/TV (p < 0.001).   There was also an increase in biomechanical properties and cortical 
geometry (Table 1).  The anti-sclerostin Ab treatment of NL animals had no effect on any of 
biochemistries.  Thus, in the NL rats, there was the expected benefit of the anti-sclerostin 
antibody.   
As we have previously reported, the high PTH group is a high bone remodeling model of 
CKD, with untreated animals having BFRs of nearly three times NL controls. There were 
significantly higher dynamic bone formation properties of the proximal tibia trabecular bone in 
the high PTH animals (Table 2) compared to the low PTH animals. In both high and low PTH 
cohorts those animals treated with anti-sclerostin antibody had higher remodeling rates compared 
to animals treated with zoledronic acid. 
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To understand the differential effects of anti-sclerostin Ab on bone in the low and high 
PTH group, we measured phosphorylated β-catenin by Western blot from total bone extracts.  In 
the CKD animals basal expression was 0.39 ± 0.18.  In the CKD animals treated witi anti-
sclerostin Ab, the expression was 0.52 ± 0.28 in the high PTH group and 0.19 ± 0.17 in the low 
PTH group (p = 0.3, with differences in the two treated groups of p = 0.008).  Phosphorylated β-
catenin expression represents degradation, and therefore less degradation would indicate a 
positive effect of the anti-sclerostin Ab in the low PTH group, consistent with the bone volume 
findings.Pharmacokinetic results:  Three of 8 CKD rats treated with anti-sclerostin AB 
developed auto-antibodies to the drug.  The animals that developed auto-antibodies did not have 
appreciably lower BV/TV than those without auto-antibodies and therefore are included in all of 
the analyses.  The pharmacokinetic curves are shown in Figure 6. Thus, auto-antibodies to anti-
human sclerostin antibody were formed, similar to previously reported in studies using 
humanized anti-OPG antibody(35,36).   
 
DISCUSSION: 
 In the present study we demonstrated that treating rats by inhibiting the activity of 
sclerostin in advanced CKD with a relatively normal PTH improved tibial trabecular bone 
volume and cortical bone geometry.  In contrast, in animals with high PTH no benefit was 
observed.   In the high PTH animals, the magnitude of hyperparathyroidism was severe, leading 
to profound cortical porosity but relatively normal tibial trabecular bone volume; neither anti-
sclerostin antibody nor zoledronic acid improved the porosity.  The phosphorylated β-catenin 
was not changed over baseline in the CKD animals treated with anti-sclerostin Ab with a high 
PTH but were appropriately decreased in the low PTH group, consistent with the lack of benefit 
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in the high PTH group.    Furthermore,  dynamic histomorphometry demonstrated that bone 
formation rate is enhanced with anti-sclerostin antibody in animals with low PTH but not in a 
high PTH setting.   Biomechanical testing demonstrated that neither anti-sclerostin antibody nor 
zoledronic acid were effective in improving the biomechanical properties of the bone, regardless 
of PTH level.  These results demonstrate that cortical bone abnormalities prevail in CKD animals 
with elevated PTH, similar to what is observed in patients with CKD(37).    However, even in 
the setting of low PTH, the improvement in bone volume did not translate to improved 
biomechanics, suggesting other factors alter bone quality in CKD.    The efficacy of anti-
sclerostin Ab to improve bone volume, geometry, and biomechanics in normal rats confirms that 
the observed lack of efficacy in the CKD animals was due to the disease state, and not because of 
auto-antibody development in rats.   These results suggest that abnormal Wnt signaling, 
especially in the high PTH group, may negate any effect of blockade of the sclerostin mediated 
pathway.  Alternatively, or additively, other factors in CKD may lead to such altered bone 
quality that anabolic changes due to the anti-sclerostin antibody are overshadowed.   
Wnt signaling is mediated through the LRP5/6 pathway that is inhibited by the 
circulating factors sclerostin and dkk-1.  PTH binds to its receptor PTH1R and activates β-
catenin signaling via multiple mechanisms: 1) binding to LRP6 to activate LRP5/LRP6 signaling 
even in the absence of Wnt, 2) cAMP signaling to directly activate β-catenin, and 3) indirectly 
via osteoclast activation which then increase β-catenin activity in osteoblasts  (Reviewed in 
(14)).  Thus, PTH can activate β-catenin through non Wnt-mediated pathways.  Mice expressing 
a constitutively active PTH1R in osteocytes leads to cAMP signaling which increases β-catenin 
and osteoblast mediated bone modeling in periosteal bone (38,39).  Deletion of LRP6 in 
osteoblasts blunts the anabolic activity of intermittent PTH administration (40) whereas deletion 
16	  
	  
of LRP5 does not (41).   Mice expressing a constitutively active PTH1R or animals receiving 
continuous infusion of PTH 1-84 (analogous to the secondary hyperparathyroidism in the 
animals in the present study) also have Wnt-dependent remodeling with increased osteoclast 
bone resorption via RANKL/OPG leading to osteoblast activation and β-catenin activation 
(39,42).   PTH suppresses expression of dkk-1 in osteoblasts, but even if dkk-1 is overexpressed, 
PTH can still activate the Wnt pathway via stabilization of phosphorylation of β-catenin (30).   In 
the present study we found increased phosphorylated (degraded) β-catenin in the high PTH 
animals compared to the low PTH animals treated with anti-sclerostin Ab suggesting that the 
elevated PTH itself does not increase β-catenin directly but more likely interferes with the 
LRP5/6 receptor.    It is important to point out that our high PTH animals had very severe 
hyperparathyroidism and other studies are needed to determine if more moderate 
hyperparathyroidism would show beneficial bone effects of anti-sclerostin antibody.   
The importance of Wnt signaling in renal osteodystrophy was first shown by Sabbagh et 
al (22) who characterized progressive secondary hyperparathyroidism with osteitis fibrosa in the 
jck mouse model of cystic kidney disease.  They found an initial increase in immunoexpression 
of sclerostin and phosphorylated β-catenin in earlier CKD, but as the disease progressed and 
secondary hyperparathyroidism and hyperphosphatemia developed there was a relative decline in 
the number of osteocytes expressing sclerostin.  They also found no further increase in the 
phosphorylated β-catenin expression with rising PTH consistent with our results of a lower 
phosphorylated β-catenin in animals with high PTH compared to low PTH.    They hypothesized 
this was due to progressive rises in PTH or in serum frizzled related protein 4 (sFRP4), another 
inhibitor of sclerostin (22).  We did not measure sFRP4 in our animals but this remains a 
possibility.    In a diabetic/atherosclerotic mouse model of early stage 2 CKD, serum levels of 
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sclerostin and Dkk1 were increased.  The administration of Dkk1 monoclonal antibody to these 
mice led to a decrease in PTH levels, an increase in circulating sclerostin levels, and an increase 
in the low bone formation rate, osteoblast and osteoclast number (43).  The PTH levels, while 
initially increased in these animals were lower at the end of the study and equivalent in both the 
vehicle and anti-dkk treated animals (43).  Those results with the anti-dkk-1 antibody parallel the 
efficacy observed in our low PTH group with anti-sclerostin antibody treatment.  Taken together 
the data suggest that PTH plays a major role in β-catenin signaling in renal osteodystrophy.     
Circulating sclerostin levels are increased in patients with progressive decline in kidney 
function, beginning as early as stage 3 CKD (44).  In contrast to other circulating biomarkers, 
these increases do not appear related to reduced renal excretion (45).   However, in patients with 
primary hyperparathyroidism, sclerostin levels are lower than euparathyroid controls (46).   In 
patients on hemodialysis, elevated sclerostin levels, but not serum Dkk-1 levels, were associated 
with increased bone mineral density at both trabecular and cortical sites by DXA and improved 
trabecular architecture by microCT in dialysis patients (13).  By multivariate analyses in a cohort 
of 60 dialysis patients, elevated sclerostin levels were only correlated with osteoblast number on 
bone biopsy.  However, sclerostin levels had positive predictive value of  0.93 for high bone 
formation rate compared to only 0.57 for intact PTH; for low bone formation rates, PTH was 
superior (21).   Dkk-1 levels were not significantly correlated with any histomorphometric 
analyses.  We also found elevated Dkk1 levels in our naturally occurring CKD animal model.  
We also saw a slight increase in the dkk-1 levels in animals treated with anti-sclerostin Ab in the 
high PTH group only, perhaps another explanation for a lack of efficacy of the anti-sclerostin Ab 
in the high PTH group.   
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In the present study, the sclerostin levels were greater in the high PTH animals compared 
to the low PTH animals.  In contrast to other studies(21), we found a positive correlation 
between PTH and blood sclerostin levels.  Given that PTH is known to suppress SOST, we then 
evaluated the levels of SOST expression in total bone extracts.  There was no difference in basal 
expression of SOST in the CKD compared to normal animals, but there was a trend towards an 
increase in the CKD animals with low PTH (treated with calcium), and a further increase in the 
with treatment with anti-sclerostin Ab.  We hypothesize that treatment with the Ab reduces 
sclerostin levels leading to upregulation of SOST.  Unfortunately we could not confirm this as 
the assay cross reacted with the Ab.  The increase in SOST with the anti-sclerostin Ab was much 
greater in the animals with low PTH.  This may suggest that PTH inhibits SOST as has been 
shown (12), and/or that the elevated calcium or FGF23 in these animals increases SOST.  
Another potential reason why we saw a positive relationship of sclerostin with PTH  may be due 
to the elevated phosphorus in these same animals.  In a study of dialysis patients, elevated 
sclerostin levels were associated with lower GFR, male sex and high phosphorus levels (44).  In 
a rat model of CKD induced by nephrectomy, parathyroidectomy and a high phosphorus diet vs 
parathyroidectomy and a normal phosphorus diet led to higher circulating sclerostin levels, lower 
bone volume, and increased bone expression of SOST, Dkk-1, and Gsk3b suggesting that 
phosphorus has a PTH independent effect to suppress Wnt signaling (47).  Treating 
normophosphatemic stage 3 to 4 CKD patients with the non calcium containing phosphate binder 
sevelamer led to a reduction in sclerostin levels, however, calcium binders had no effect on 
sclerostin levels despite effectively lowering phosphorus (48).  In the present study we utilized 
calcium in the drinking water to suppress PTH, which also acts like a phosphate binder to lower 
phosphorus levels.  Thus it is possible that the elevated sclerostin levels in the high PTH group 
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are due to hyperphosphatemia, and/or that the calcium administration used to lower PTH 
decreases sclerostin levels  (21).  Clearly more work is needed to understand the regulation of 
SOST, especially in the setting of CKD. 
Calcium (or lower PTH) also increases FGF23 levels in our animals as we have 
previously reported (27).  In the present study, anti-sclerostin Ab had no effect on FGF23 levels 
although there was a trend towards lowering of FGF23 levels in the low PTH group.  However, 
the variability of FGF23 in this naturally occurring animal model of CKD was such that this did 
not reach significance.   However, treatment with anti-dkk-1 Ab in mice with early stage of CKD 
did not alter FGF23 levels (43).  PTH also stimulates FGF23 via cAMP and Wnt signaling (11) 
and thus we would have expected lower, not higher FGF23 levels in our low PTH animals.  In 
addition, the low PTH group had elevated FGF23 that was unaffected by anti-sclerostin Ab.  
This implies that the calcium treatment used to lower PTH likely has a direct effect on FGF23 
synthesis.   Calcium treatment also led to more animals with arterial calcification, an observation 
that was moderated by both zoledronic acid and anti-sclerostin antibody treatment.  Similarly, 
Fang et al found that anti-dkk-1 therapy in CKD animals reduced arterial calcification(43).  
Whether sclerostin plays a pathogenic role in arterial calcification or the expression is simply a 
marker of osteo-chondrogenic transformation remains to be seen.   
In summary, our study is the first to test the efficacy of anti-sclerostin Ab in the setting of 
renal osteodystrophy.   In our rat model of slowly progressive CKD, the antibody enhanced bone 
formation rates, trabecular bone volume and cortical geometry, but only in the setting of low 
PTH and this did not translate to improved biomechanical properties.  In the animals with severe 
secondary hyperparathyroidism, the antibody was not efficacious, most likely due to PTH 
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interference of Wnt signaling by alteration of the LRP5/6 receptor, or through effects of changes 
in phosphorus or FGF23.     
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Table 1:   Bone CT and Biomechanical Results 
 Proximal	  tibia	   Femoral	  mid-­‐diaphysis	  
 BV/TV	  
(%)	  
Cortical	  
Porosity	  
(%)	  
Ultimate	  
Force	  (N)	  
	  Stiffness	  
(N/mm)	  
Energy	  
to	  failure	  
(mJ)	  
Ultimate	  
Stress	  
(MPa)	  
Modulus	  
(MPa)	  
Toughness	  
(MJ/m3)	  
Cortical	  
thickness
(mm)	  
Cortical	  
bone	  
area	  
(mm2)	  
Cortical	  
porosity	  
(%)	  
CSMI	  
(mm4)	  
CKD	  High	  PTH	  
CTL	   10.2	  
±	  1.9	  
2.4	  ±	  
1.7	  
208.9	  ±	  
27.7	  
456.7	  ±	  
64.6	  
93.8	  ±	  
18.5	  
100	  ±	  
16	  
3686	  ±	  
546	  
2.7	  ±	  0.6	   0.58	  ±	  
0.10	  
7.4	  ±	  
0.4	  
2.8	  ±	  
2.9	  
22.4	  ±	  
1.8	  
Scl-­‐
Ab	  
11.3	  
±	  3.7	  
7.4	  ±	  
8.5	  
200.5	  ±	  
48.7	  
471.9	  ±	  
99.0	  
83.8	  ±	  
35.4	  
92	  ±	  28	   3527	  ±	  
916	  
2.3	  ±	  1.1	   0.49	  ±	  
0.19	  
8.1	  ±	  
0.4	  	  
7.2	  ±	  
5.8	  
23.9	  ±	  
2.2	  	  
Zol	   13.0	  
±	  4.9	  
5.9	  ±	  
6.4	  
211.2	  ±	  
38.3	  
428.8	  ±	  
59.7	  
96.6	  ±	  
30.0	  
104	  ±	  
25	  
3570	  ±	  
683	  
2.8	  ±	  0.9	   0.54	  ±	  
0.18	  
7.8	  ±	  
0.6	  
6.2	  ±	  
7.0	  
21.9	  ±	  
2.7	  
CKD	  Low	  PTH	  
CTL	   21.1	  ±	  
3.6	  
1.3	  ±	  
0.5	  
256.7	  ±	  
20.2	  
561.6	  ±	  
47.5	  
112.6	  ±	  
15.2	  
115	  ±	  9	   4306	  ±	  
419	  
2.9	  ±	  0.5	   0.80	  ±	  
0.07	  
8.8	  ±	  
0.7	  
4.5	  ±	  
8.3	  
23.6	  ±	  
2.5	  
Scl-­‐
Ab	  
25.6	  ±	  
4.3*	  
1.5	  ±	  
0.7	  
295.1	  ±	  
27.8	  
593.9	  ±	  
31.1	  
126.6	  ±	  
29.7	  
127	  ±	  
19	  
4224	  ±	  
555	  
3.3	  ±	  0.9	   0.80	  ±	  
0.05	  
9.0	  ±	  
0.7	  	  
0.77	  ±	  
0.48	  
25.7	  ±	  
3.1	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Zol	   20.9	  ±	  
3.2	  
1.4	  ±	  
0.7	  
272.3	  ±	  
24.3	  
567.6	  ±	  
43.9	  
111.9	  ±	  
23.5	  
124	  ±	  
11	  
4349	  ±	  
667	  
3.0	  ±	  0.7	   0.82	  ±	  
0.06	  
8.9	  ±	  
0.8	  
0.71	  ±	  
0.57	  
23.9	  ±	  
3.7	  
Normal	  animals	  
CTL	   10.2	  ±	  
1.9	  
1.0	  ±	  
0.4	  
268.0	  +	  
21.0	  
562.4	  ±	  
37.5	  
131.1	  ±	  
29.1	  
116	  ±	  
16	  
3767	  ±	  
320	  
3.6	  ±	  1.0	   0.73	  ±	  
0.05	  
8.6	  ±	  
0.3	  
1.8	  ±	  
0.6	  
26.4	  ±	  
2.4	  
Scl-­‐
Ab	  
16.0	  ±	  
1.9*	  
1.2	  ±	  
0.6	  
339.5	  ±	  
31.3+	  
663.5	  ±	  
101.9*	  
169.7	  ±	  
29.5*	  
114	  ±	  
12	  
3254	  ±	  
443*	  
3.9	  ±	  0.9	   0.79	  ±	  
0.03	  *	  
10.3	  ±	  
0.6+	  
1.3	  ±	  
0.3	  
36.8	  ±	  
3.5+	  
 
CTL= control or no treatment; Scl-Ab = treatment with anti-sclerostin Ab; Zol = treatment with zoledronic acid; CSMI = 
cross sectional moment of inertia.    Data presented as mean and standard deviation. 
The CKD animals were compared by two-way ANOVA evaluating the effect of PTH and treatment.  There were significant 
differences (p < 0.01) by PTH group for all bone parameters.  Treatment with sclerostin Ab was different than control for 
trabecular bone volume (p = 0.03), cortical bone area (P = 0.05), and CSMI (p = 0.043) with no  differences among treatments 
for the other parameters.  Data are mean ± SD. 
The Normal animals with and without treatment with anti-sclerostin Ab were compared by t-test.  * = p < 0.05, + = p < 0.01   
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Table 2. 
 
 N, # MAR, 
um/day 
MS/BS, % BFR/BS, 
um3/um2/year 
CKD High PTH 
CTL 11 2.2 + 1.1 31 + 8 280 + 156 
Scl-Ab 12 2.8 + 1.7 29 + 8 323 + 221 
Zol 9 2.0 + 1.0 21 + 10 166 + 117 
CKD Low PTH 
CTL 10 1.2 + 0.3 11 + 5 49 + 18 
Scl-Ab 12 1.2 + 0.6 28 + 17 154 + 154 
Zol 9 0.4 + 0.2 5 + 4 8 + 7 
Normal animals 
CTL 8 1.2 + 0.3 21 + 7 94 + 42 
Scl-Ab 8 1.4 + 0.3 24 + 9 133 + 66 
 
CTL= control or no treatment; Scl-Ab = treatment with anti-sclerostin Ab; Zol = treatment with 
zoledronic acid; MAR = mineral apposition rate; MS/BS = mineralizing surface per bone 
surface; BFR/BS = bone formation rate per bone surface. Data presented as mean and standard 
deviation.  The CKD animals were compared by two-way ANOVA evaluating the effect of PTH 
and treatment.  There were significant PTH and drug effects for MAR, MB/BS and BFR/BS, 
animals with higher PTH had values compared to low PTH; animals treated with Scl-AB had 
higher MAR and MS/BS compared both CTL and ZOL. The Normal animals with and without 
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treatment with anti-sclerostin Ab were compared by t-test but there was no significant difference 
for any parameter. 
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FIGURE LEGENDS: 
Figure 1:  Schematic of study design:  CKD animals were fed a casein based diet beginning at 
24 weeks, then given drinking water with or without 3% calcium beginning at 25 weeks.  Drug 
administration began at 30 weeks of age, and sacrifice was at 35 weeks.  Data are mean ± SD.  * 
= p < 0.05 for comparison between animals given calcium or no calcium, + = p < 0.05 for anti-
sclerostin Ab versus control.  Final n for each group is included in the boxes.   
 
Figure 2:  Biochemical results:  At 35 weeks, the CKD animals had blood assessed for calcium 
(A), phosphorus (B), FGF23 (C), and dkk-1 (D) levels.  The animals with high PTH (left) were 
compared to those treated with calcium and with low PTH (right) by two way ANOVA 
examining effect of PTH and treatment.  For calcium (p = 0.016), and FGF23 (p = 0.0003) there 
was a difference between the high and low PTH (large bar across top), but no effect of treatments 
(groups of 3 bars).  For phosphorus, there was a significant effect of both PTH (p < 0.001), and a 
significant effect of treatment (p < 0.001) due to significant effects of zoledronic acid to increase 
phosphorus levels compared to both sclerostin Ab treated and control treated animals (both p < 
0.001).  In contrast, for dkk-1, there was no effect by PTH group, but the treatment effect was 
significant (p = 0.004), with zoledronic acid lowering the dkk-1 compared to both control (p = 
0.03).   
 
Figure 3:  Sclerostin levels and SOST expression:  Figure 3A shows the relationship between 
the sclerostin and PTH levels (r = 0.73, p < 0.001) for the CKD animals.  Those animals treated 
with anti-sclerostin Ab are not included due to interference with the assay.   Figure 3B shows the 
expression of total bone SOST with and without treatment with anti-sclerostin Ab.  There was an 
26	  
	  
increase with Ab treatment in only the low PTH animals (* p < 0.001).  The expression level of 
SOST in the low PTH animals was significantly greater than in the high PTH animals (#, p < 
0.001).  Data are mean ± SD. 
 
Figure 4:  Aorta arch calcification:  At 35 weeks, the aorta arch was dissected free and 
analyzed for calcium content after HCl extraction, normalizing for tissue weight. By 2-way 
ANOVA there was no significant difference between the groups, although there was a trend 
towards increased calcification in the calcium treated control animals; an effect that appeared 
attenuated by both drug treatments.  The bar graphs represent the mean ± SD. The box insets in 
each bar indicate the percentage of animals in each group with significant calcification (defined 
as > 5.26 umol/g which is the normal littermate average value of mean + 2SD). The dashed line 
represents the mean value from the normal littermate animals.  
 
Figure 5:  Bone Results:  At 35 weeks, bone from the CKD animals was assessed by microCT 
for proximal tibial trabecular bone volume (A), cortical porosity (B), femur ultimate force (C) 
and for femur cortical bone endocortical perimeter (D) and ultimate force (D).  The animals with 
high PTH (left) were compared to those treated with calcium and with low PTH (right) by two 
way ANOVA examining effect of PTH and treatment.  For bone volume,  porosity, and ultimate 
force (all p < 0.001) there was a difference between the high and low PTH.  There was a positive 
effect of treatment on bone volume with the sclerostin Ab increasing the volume more than 
control (p = 0.008).  There was no effect of treatment for cortical porosity or ultimate force.  The 
dashed line represents the mean value from the normal littermate animals.  Figure E shows 
representative images by microCT of the animals.  Cortical porosity (blue arrow) was prominent 
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in the high PTH animals and not affected by drug treatment.  Figures 5 A through D are 
presented as mean ± SD. 
Figure 6:   Pharmacokinetic results:  Eight animals had blood drawn for measurement of the 
anti-sclerostin antibody 6 and 24 hours after the first and fifth dose..  The y-axis represents the 
measured level of the anti-sclerostin antibody (BPS804) in the blood of each animal.    Each 
symbol represents a different animal.  * = the presence of auto-antibodies in serum at that time 
point.  For the animal denoted by the open square (++), levels were undetectable at dose 5 and 
autoantibodies were present.  
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Week	  30	  
High	  	  PTH	  
group	  
An?-­‐Scleros?n	  Ab	  (n	  =	  11)	  
PTH	  =	  43	  ±	  41	  pg/ml	  
An?-­‐Scleros?n	  Ab	  (n	  =	  12)	  
PTH	  =	  2704	  ±	  2548	  pg/ml*+	  
Zoledronic	  Acid	  (n	  =	  9)	  
PTH	  =	  33	  ±	  17	  pg/ml	  
Control	  (n	  =	  10)	  
PTH	  =	  58	  ±	  13	  pg/ml	  
Control	  (n	  =	  11)	  
PTH	  =1560	  ±	  860	  pg/ml*	  
Zoledronic	  Acid	  (n	  =	  10)	  
PTH	  =2357	  ±	  1895	  pg/ml*	  
Ca	  =	  9.2	  ±	  1.7	  	  
Pi	  =	  6.9	  ±	  2.0	  
PTH	  =	  634	  ±	  460	  
BUN	  =	  44	  ±	  1	  
Ca	  =	  10.1±	  1.7	  
Pi	  =	  7.1	  ±	  2.5	  
PTH=	  466	  ±	  264	  
BUN	  =	  42	  ±	  1	  
Ca	  =	  10.2	  ±	  1.9	  
Pi	  =	  7.8	  ±	  1.7	  
PTH	  =	  120	  ±	  100	  
BUN	  =	  50	  ±	  2	  
Ca	  =	  10.1	  ±	  2.0	  
Pi	  =	  7.2	  ±	  2.2	  
PTH	  =759	  ±	  778*	  
BUN	  =	  46	  ±	  1.4	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Figure	  2A	  
P	  =	  0.016	  for	  low	  vs.	  high	  PTH;	  no	  eﬀect	  of	  treatment	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